Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) – Pipeline Review, H2 2017’, provides in depth analysis on Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal and Metabolic Disorders under development targeting Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)

The report reviews Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics and enlists all their major and minor projects

The report assesses Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

BirchBioMed Inc

Bristol-Myers Squibb Co

CanBas Co Ltd

Ensemble Therapeutics Corp

F. Hoffmann-La Roche Ltd

Globavir Biosciences Inc

Incyte Corp

Innovent Biologics Inc

IO Biotech ApS

Jiangsu Hengrui Medicine Co Ltd

Kyowa Hakko Kirin Co Ltd

Netherlands Translational Research Center BV

NewLink Genetics Corp

Pfizer Inc

Redx Pharma Plc

Regen BioPharma Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Overview 9

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Therapeutics Development 10

Products under Development by Stage of Development 10

Products under Development by Therapy Area 11

Products under Development by Indication 12

Products under Development by Companies 16

Products under Development by Universities/Institutes 21

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Therapeutics Assessment 23

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Companies Involved in Therapeutics Development 29

BirchBioMed Inc 29

Bristol-Myers Squibb Co 29

CanBas Co Ltd 30

Ensemble Therapeutics Corp 30

F. Hoffmann-La Roche Ltd 31

Globavir Biosciences Inc 31

Incyte Corp 32

Innovent Biologics Inc 33

IO Biotech ApS 34

Jiangsu Hengrui Medicine Co Ltd 34

Kyowa Hakko Kirin Co Ltd 34

Netherlands Translational Research Center BV 35

NewLink Genetics Corp 35

Pfizer Inc 36

Redx Pharma Plc 37

Regen BioPharma Inc 37

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Drug Profiles 38

AI-001 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

BMS-986205 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

dcellvax - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

epacadostat - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

F-001287 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Galanal - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

GBV-1012 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

GBV-1028 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

HTI-1090 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

indoximod - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

IO-101 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

IO-102 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

KHK-2455 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Monoclonal Antibody to Inhibit IDO and TDO for Oncology - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

NLG-802 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Oligonucleotide to Inhibit IDO1 for Pancreatic Ductal Adenocarcinoma - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

PF-06840003 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

RG-70099 - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

Small Molecule to Inhibit Indoleamine 2,3-Dioxygenase for Oncology - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Small Molecule to Inhibit Indoleamine 2,3-Dioxygenase for Oncology - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Small Molecules to Inhibit IDO and TDO for Oncology - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

Small Molecules to Inhibit IDO for Oncology - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

Small Molecules to Inhibit IDO for Oncology and Gastrointestinal Disorders - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Small Molecules to Inhibit IDO for Solid Tumor - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Small Molecules to Inhibit IDO-1 for Lewis Lung Cancer - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

Small Molecules to Inhibit IDO-1 for Pancreatic Cancer - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

Small Molecules to Inhibit IDO/TDO for Oncology - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

Small Molecules to Inhibit IDO1 for Oncology - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Small Molecules to Inhibit IDO1 for Oncology - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

Small Molecules to Inhibit IDO1 for Oncology - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

Small Molecules to Inhibit IDO1 for Skin Cancer and Lung Cancer - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

Vaccine to Target PDL1 and IDO for Metastatic Melanoma - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Dormant Products 87

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Discontinued Products 89

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC

1.13.11.52) - Product Development Milestones 90

Featured News & Press Releases 90

Oct 30, 2017: NewLink Genetics Announces FDA Orphan-Drug Designation for Indoximod 90

Oct 12, 2017: IO Biotech Appoints Dr. Eva Ehrnrooth as Chief Medical Officer 90

Sep 09, 2017: Progression-Free Survival Data from ECHO-202 Trial of Incyte's Epacadostat in Combination with Merck's KEYTRUDA (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma 91

Sep 07, 2017: Updated Data for Indoximod Plus KEYTRUDA Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma 92

Aug 30, 2017: New Data for Epacadostat in Combination with KEYTRUDA (pembrolizumab) Demonstrate Durable Responses in Patients with Advanced Melanoma 93

Jul 28, 2017: NewLink Genetics provides Updates of Indoximod Program 94

Jul 27, 2017: NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802 95

Jul 10, 2017: NewLink Genetics Receives Notice of Allowance from USPTO Covering Indoximod Salts and Prodrugs 95

Jun 23, 2017: Positive Phase 1b Data for NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia Presented at the European Hematologic Association Congress in Madrid, Spain 95

Jun 05, 2017: NewLink Genetics' Indoximod + PROVENGE Results in Statistically Significant Improvement in Radiographic Progression-Free Survival for Patients with Metastatic Castration Resistant Prostate Cancer in Phase 2 Trial 96

Jun 05, 2017: Clinical Trial Data for Combination of Epacadostat and Opdivo (nivolumab) Demonstrate Durable Clinical Responses in Patients with Melanoma and Head and Neck Cancer 97

Jun 05, 2017: Incyte Analyst and Investor Event to Highlight Clinical Data Presentations from ASCO 2017 97

Jun 05, 2017: Updated Data from ECHO-202 Trial of Incyte's Epacadostat in Combination with Merck's KEYTRUDA (Pembrolizumab) Demonstrate Clinical Activity across Multiple Tumor Types 97

Jun 03, 2017: Combination of Incyte's Epacadostat plus Merck's KEYTRUDA (pembrolizumab) Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer 98

Jun 02, 2017: Results from Clinical Trial of Indoximod Plus Chemotherapy for Patients with Metastatic Breast Cancer 99

Appendix 100

Methodology 100

Coverage 100

Secondary Research 100

Primary Research 100

Expert Panel Validation 100

Contact Us 100

Disclaimer 101

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 10

Number of Products under Development by Therapy Areas, H2 2017 11

Number of Products under Development by Indications, H2 2017 12

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 14

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 15

Number of Products under Development by Companies, H2 2017 16

Products under Development by Companies, H2 2017 17

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 18

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 19

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 20

Number of Products under Investigation by Universities/Institutes, H2 2017 21

Products under Investigation by Universities/Institutes, H2 2017 22

Number of Products by Stage and Mechanism of Actions, H2 2017 24

Number of Products by Stage and Route of Administration, H2 2017 26

Number of Products by Stage and Molecule Type, H2 2017 28

Pipeline by BirchBioMed Inc, H2 2017 29

Pipeline by Bristol-Myers Squibb Co, H2 2017 30

Pipeline by CanBas Co Ltd, H2 2017 30

Pipeline by Ensemble Therapeutics Corp, H2 2017 31

Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 31

Pipeline by Globavir Biosciences Inc, H2 2017 32

Pipeline by Incyte Corp, H2 2017 33

Pipeline by Innovent Biologics Inc, H2 2017 33

Pipeline by IO Biotech ApS, H2 2017 34

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 34

Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 35

Pipeline by Netherlands Translational Research Center BV, H2 2017 35

Pipeline by NewLink Genetics Corp, H2 2017 36

Pipeline by Pfizer Inc, H2 2017 36

Pipeline by Redx Pharma Plc, H2 2017 37

Pipeline by Regen BioPharma Inc, H2 2017 37

Dormant Products, H2 2017 87

Dormant Products, H2 2017 (Contd..1), H2 2017 88

Discontinued Products, H2 2017 89

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 10

Number of Products under Development by Therapy Areas, H2 2017 11

Number of Products under Development by Top 10 Indications, H2 2017 12

Number of Products by Mechanism of Actions, H2 2017 23

Number of Products by Stage and Mechanism of Actions, H2 2017 23

Number of Products by Routes of Administration, H2 2017 25

Number of Products by Stage and Routes of Administration, H2 2017 25

Number of Products by Molecule Types, H2 2017 27

Number of Products by Stage and Molecule Types, H2 2017 27

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports